Log in
NASDAQ:REGN

Regeneron Pharmaceuticals News Headlines

$555.79
-11.25 (-1.98 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$555.54
Now: $555.79
$576.00
50-Day Range
$544.75
MA: $576.02
$607.98
52-Week Range
$303.49
Now: $555.79
$664.64
Volume900,357 shs
Average Volume1.14 million shs
Market Capitalization$59.13 billion
P/E Ratio21.52
Dividend YieldN/A
Beta0.51

Headlines

Regeneron Pharmaceuticals (NASDAQ REGN) News Headlines Today

Source:
SourceHeadline
The Latest: China says latest outbreak appears containedThe Latest: China says latest outbreak appears contained
marketbeat.com - October 28 at 10:31 PM
The Latest: Anchorage officials say city on dangerous pathThe Latest: Anchorage officials say city on 'dangerous path'
marketbeat.com - October 28 at 8:11 PM
The Latest: Minnesota cautions against traditional HalloweenThe Latest: Minnesota cautions against traditional Halloween
marketbeat.com - October 28 at 7:09 PM
The Latest: South Dakota sees record virus hospitalizationsThe Latest: South Dakota sees record virus hospitalizations
marketbeat.com - October 28 at 6:00 PM
The Latest: Kansas reports about 3,400 new cases over 2 daysThe Latest: Kansas reports about 3,400 new cases over 2 days
marketbeat.com - October 28 at 5:29 PM
The Latest: Italy hits daily high of nearly 25,000 casesThe Latest: Italy hits daily high of nearly 25,000 cases
marketbeat.com - October 28 at 3:38 PM
The Latest: US to buy initial antibody doses from Eli LillyThe Latest: US to buy initial antibody doses from Eli Lilly
marketbeat.com - October 28 at 11:44 AM
Possible safety issue spurs pause of COVID-19 antibody studyPossible safety issue spurs pause of COVID-19 antibody study
marketbeat.com - October 13 at 4:41 PM
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $609.00Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $609.00
marketbeat.com - October 13 at 11:15 AM
AstraZeneca (LON:AZN) Setbacks Dont Stop This Companys Comeback (REGN)AstraZeneca (LON:AZN) Setbacks Don't Stop This Company's Comeback (REGN)
marketbeat.com - October 12 at 11:20 AM
The Latest: New Mexico loses ground in COVID-19 spread fightThe Latest: New Mexico loses ground in COVID-19 spread fight
marketbeat.com - October 9 at 10:41 PM
The Latest: RI university issues order for frats, sororitiesThe Latest: RI university issues order for frats, sororities
marketbeat.com - October 9 at 9:16 PM
The Latest: Judge wont block NY plan to limit gatheringsThe Latest: Judge won't block NY plan to limit gatherings
marketbeat.com - October 9 at 7:41 PM
The Latest: Virus cluster found at Alaska hockey tournamentThe Latest: Virus cluster found at Alaska hockey tournament
marketbeat.com - October 9 at 6:18 PM
The Latest: Gov. Justice: Bars near WVU can open TuesdayThe Latest: Gov. Justice: Bars near WVU can open Tuesday
marketbeat.com - October 9 at 4:35 PM
Lilly seeks emergency use of its antibody drug for COVID-19Lilly seeks emergency use of its antibody drug for COVID-19
marketbeat.com - October 7 at 8:54 AM
Regeneron (NASDAQ:REGN) Stock a Buy? Key Biotech Company Fighting COVID-19Regeneron (NASDAQ:REGN) Stock a Buy? Key Biotech Company Fighting COVID-19
marketbeat.com - October 6 at 9:52 AM
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by BidaskClubRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by BidaskClub
marketbeat.com - August 26 at 1:26 AM
Benchmark Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to HoldBenchmark Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold
marketbeat.com - August 20 at 7:39 AM
Huge Gains for Regeneron (NASDAQ:REGN) As New Covid Drug Cocktail Hits Late-Stage (REGN)Huge Gains for Regeneron (NASDAQ:REGN) As New Covid Drug Cocktail Hits Late-Stage (REGN)
marketbeat.com - August 4 at 10:31 AM
Regeneron Once Again Earns #1 Ranking in Science Magazines Top Biopharma Companies to Work ForRegeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
prnewswire.com - October 29 at 11:53 PM
Regenerons Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer PatientsRegeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients
nasdaq.com - October 29 at 6:53 PM
Sanofi/Regeneron prevail in European patent dispute with Amgen over cholesterol drugsSanofi/Regeneron prevail in European patent dispute with Amgen over cholesterol drugs
seekingalpha.com - October 29 at 1:53 PM
Regeneron Posts Positive Data For Covid-19 Treatment; Lung Cancer Drug AdvancesRegeneron Posts Positive Data For Covid-19 Treatment; Lung Cancer Drug Advances
finance.yahoo.com - October 29 at 1:53 PM
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Weeks ReleaseRegeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
finance.yahoo.com - October 29 at 1:53 PM
FDA accepts Regeneron application for Libtayo for certain lung cancer patientsFDA accepts Regeneron application for Libtayo for certain lung cancer patients
seekingalpha.com - October 29 at 8:49 AM
FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
finance.yahoo.com - October 29 at 8:49 AM
Regeneron’s Covid-19 Therapy Reduces Viral Load, Need for CareRegeneron’s Covid-19 Therapy Reduces Viral Load, Need for Care
msn.com - October 28 at 11:43 PM
Did Regeneron Just Revive Hopes About Beating COVID-19?Did Regeneron Just Revive Hopes About Beating COVID-19?
msn.com - October 28 at 11:43 PM
Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA AuthorizationRegeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA Authorization
forbes.com - October 28 at 11:43 PM
Regeneron Says COVID-19 Antibody Cocktail Reduced Viral Load, Need For Medical Care In Late-Stage TrialRegeneron Says COVID-19 Antibody Cocktail Reduced Viral Load, Need For Medical Care In Late-Stage Trial
benzinga.com - October 28 at 10:00 PM
Regeneron says its COVID-19 antibody treatment cut medical visits in trialRegeneron says its COVID-19 antibody treatment cut medical visits in trial
nasdaq.com - October 28 at 6:43 PM
Regeneron Covid-19 Therapy Reduces Viral Load, Need for CareRegeneron Covid-19 Therapy Reduces Viral Load, Need for Care
msn.com - October 28 at 6:43 PM
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical AttentionRegeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
finance.yahoo.com - October 28 at 6:43 PM
CORRECTED-Regeneron says its COVID-19 antibody treatment cut medical visits in trialCORRECTED-Regeneron says its COVID-19 antibody treatment cut medical visits in trial
finance.yahoo.com - October 28 at 6:43 PM
Regeneron: Trial COVID-19 drug cocktail cut virus load in more peopleRegeneron: Trial COVID-19 drug cocktail cut virus load in more people
finance.yahoo.com - October 28 at 6:43 PM
A Strong Move in Shares of Renewable Energy Group is in the ChartsA Strong Move in Shares of Renewable Energy Group is in the Charts
stocknews.com - October 28 at 11:04 AM
Why Eli Lilly’s September Earnings Disappointed Wall StreetWhy Eli Lilly’s September Earnings Disappointed Wall Street
finance.yahoo.com - October 27 at 8:55 AM
Were Hedge Funds Right About Embracing Regeneron Pharmaceuticals Inc (REGN)?Were Hedge Funds Right About Embracing Regeneron Pharmaceuticals Inc (REGN)?
finance.yahoo.com - October 26 at 6:40 PM
Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific MeetingsDupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
finance.yahoo.com - October 26 at 8:15 AM
How Much Is Moderna Really Worth?How Much Is Moderna Really Worth?
finance.yahoo.com - October 23 at 9:41 AM
Can a Coronavirus Antibody Treatment Knock Out Moderna?Can a Coronavirus Antibody Treatment Knock Out Moderna?
finance.yahoo.com - October 23 at 9:41 AM
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other UpdatesBiotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
finance.yahoo.com - October 22 at 1:30 PM
Is Regeneron a Buy Before Nov. 3?Is Regeneron a Buy Before Nov. 3?
finance.yahoo.com - October 22 at 8:29 AM
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN)Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN)
finance.yahoo.com - October 21 at 7:02 PM
3 Top Genomics Stocks to Buy for 2021 and Beyond3 Top Genomics Stocks to Buy for 2021 and Beyond
stocknews.com - October 20 at 6:37 PM
How Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About VaccinesHow Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About Vaccines
finance.yahoo.com - October 20 at 8:25 AM
How Regenerons Coronavirus Antibody Treatment Differs From Convalescent PlasmaHow Regeneron's Coronavirus Antibody Treatment Differs From Convalescent Plasma
msn.com - October 19 at 2:09 PM
 Brokerages Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Post Earnings of $7.21 Per Share Brokerages Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Will Post Earnings of $7.21 Per Share
americanbankingnews.com - October 18 at 7:29 AM
Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Media Impact Score of -1.86Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Media Impact Score of -1.86
americanbankingnews.com - October 16 at 2:42 PM
European advisory group backs expanded use of Regeneron/Sanofis DupixentEuropean advisory group backs expanded use of Regeneron/Sanofi's Dupixent
seekingalpha.com - October 16 at 1:01 PM
Regenerons (REGN) Inmazeb Ebola Treatment Gets FDA ApprovalRegeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
nasdaq.com - October 15 at 2:29 PM
U.S. FDA approves Regenerons drug as first treatment for Ebola virusU.S. FDA approves Regeneron's drug as first treatment for Ebola virus
nasdaq.com - October 14 at 6:22 PM
Regenerons Inmazeb becomes first FDA-approved Ebola treatmentRegeneron's Inmazeb becomes first FDA-approved Ebola treatment
seekingalpha.com - October 14 at 6:22 PM
Regenerons drug becomes first FDA-approved Ebola virus treatmentRegeneron's drug becomes first FDA-approved Ebola virus treatment
nasdaq.com - October 14 at 6:22 PM
Trumps Medicine: A Look At Regenerons Antibody CocktailTrump's Medicine: A Look At Regeneron's Antibody Cocktail
seekingalpha.com - October 14 at 1:21 PM
Biotech Stock Roundup: REGN, GILDs Coronavirus News & Other Pipeline UpdatesBiotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
finance.yahoo.com - October 14 at 1:21 PM
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $609.00 by Analysts at Morgan StanleyRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $609.00 by Analysts at Morgan Stanley
americanbankingnews.com - October 13 at 1:05 PM
Regeneron: Phase 3 Trial Shows Dupixent Significantly Reduces Severe Asthma Attacks In ChildrenRegeneron: Phase 3 Trial Shows Dupixent Significantly Reduces Severe Asthma Attacks In Children
nasdaq.com - October 13 at 4:56 AM
Trumps Endorsement A Double-Edged Sword For RegeneronTrump's Endorsement A Double-Edged Sword For Regeneron
msn.com - October 12 at 1:54 PM
Regeneron CEO Says More Testing Needed For Antibody Cocktail After Trump Touted It As COVID-19 CureRegeneron CEO Says More Testing Needed For Antibody Cocktail After Trump Touted It As COVID-19 'Cure'
feeds.benzinga.com - October 12 at 12:54 AM
Regeneron CEO cautions Trump’s results are ‘a case of one,’ and coronavirus drug needs more testingRegeneron CEO cautions Trump’s results are ‘a case of one,’ and coronavirus drug needs more testing
msn.com - October 12 at 12:13 AM
: Regeneron CEO cautions Trump’s results are ‘a case of one,’ and coronavirus drug needs more testing: Regeneron CEO cautions Trump’s results are ‘a case of one,’ and coronavirus drug needs more testing
marketwatch.com - October 11 at 8:41 PM
The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The PipelineThe Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline
benzinga.com - October 11 at 4:26 PM
After President Trump Gets Experimental Antibody Cocktail, Is Regeneron Stock a Good Coronavirus Buy?After President Trump Gets Experimental Antibody Cocktail, Is Regeneron Stock a Good Coronavirus Buy?
fool.com - October 10 at 7:58 AM
Antibody Drugs Touted by Trump Could Be Next to Get Authorized for Covid-19Antibody Drugs Touted by Trump Could Be Next to Get Authorized for Covid-19
wsj.com - October 9 at 6:35 PM
Demand surges for Regeneron drug that Trump claims ‘cures’ Covid-19Demand surges for Regeneron drug that Trump claims ‘cures’ Covid-19
msn.com - October 9 at 2:49 PM
Regeneron Gains on EUA Request for Coronavirus TreatmentRegeneron Gains on EUA Request for Coronavirus Treatment
nasdaq.com - October 9 at 2:49 PM
Trump’s Regeneron Treatment Is a Tangled Ethical MessTrump’s Regeneron Treatment Is a Tangled Ethical Mess
barrons.com - October 8 at 6:10 PM
Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021
benzinga.com - October 8 at 3:50 PM
This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.